Envoy Therapeutics, Inc. today announced that it has entered into a multi-year research collaboration agreement with an affiliate of Merck & Co., Inc. to discover novel diabetes and obesity drug targets.
Under the agreement, Envoy will use its proprietary bacTRAP® technology to identify proteins expressed specifically in certain cell types. Merck will then work to identify and develop compounds that modulate protein targets with therapeutic potential for the treatment of metabolic disorders. Merck will pay Envoy an upfront fee and research funding. In addition, Envoy is eligible to receive payments upon achievement of certain milestones associated with development of drug candidates and royalties on any products derived from the collaboration.
“Obesity and diabetes have become epidemics with horrific mortality rates and devastating social stigmas,” stated Brad Margus, Co-founder and Chief Executive Officer of Envoy. “We’re thrilled that our technology will be applied towards discovering drug candidates for the growing millions of patients that suffer from these conditions.”
Read the full article at AOL Money & Finance
Popularity: 6% [?]
